

Addressing Significant Unmet Needs in CNS



Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Marketed
NUPLAZID® (pimavanserin)¹	Parkinson's Disease Psychosis						
Trofinetide^{2 3}	Rett Syndrome						
Pimavanserin⁴	Negative Symptoms of Schizophrenia						
ACP-204³	Alzheimer's Disease Psychosis						
ASO Programs⁵	SYNGAP1; Rett Syndrome; Undisclosed						
Other Programs	Neuropsychiatric Symptoms						

¹ NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

² Acadia has an exclusive license to develop and commercialize trofinetide in North America from Neuren Pharmaceuticals.

³ Trofinetide and ACP-204 are investigational agents, and the safety and efficacy of these agents have not been established. There is no guarantee these investigational agents will be filed with or approved by any regulatory agency.

⁴ Safety and Efficacy of NUPLAZID for the treatment of negative symptoms of schizophrenia have not been established or approved by the FDA.

⁵ Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases.

ASO = Antisense oligonucleotide.

Provided January 10, 2023 as part of an oral presentation and is qualified by such; contains forward-looking statements; actual results may vary materially; Acadia disclaims any duty to update.